Patents by Inventor Ulf Bruggemeier

Ulf Bruggemeier has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20060188882
    Abstract: The invention provides a human PDE1C which is associated with the cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular disorders, gastrointestinal and liver diseases, cancer disorders, neurological disorders, respiratory Diseases and urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE1C as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 24, 2006
    Applicant: BAYER HEALTHCARE AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060165679
    Abstract: The invention provides a human VPAC2 which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardio-vascular diseases, hematological diseases, genitourinary diseases, inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of VPAC2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: April 25, 2003
    Publication date: July 27, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Publication number: 20060166911
    Abstract: The invention provides a human PDE11A which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, liver disease and genito-urinary diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE11A as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: September 18, 2003
    Publication date: July 27, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060160088
    Abstract: The invention provides a human GPR40 which is associated with the hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, disorders of the peripheral and central nervous system, gastrointestinal diseases, respiratory diseases, metabolic disease, cancer, cardiovascular diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR40 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 4, 2004
    Publication date: July 20, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Publication number: 20060160132
    Abstract: The invention provides a human HM74a which is associated with the disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, urological diseases, respiratory diseases and gastroen-terological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, hematological diseases, cancer, inflammation, uro-logical diseases, respiratory diseases and gastroenterological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of HM74a as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: February 5, 2004
    Publication date: July 20, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Holger Summer
  • Publication number: 20060160083
    Abstract: The invention provides a human GPR14 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urological diseases, endocrinological diseases and cancer. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, urological diseases, endocrinological diseases and cancer. The invention also features compounds which bind to and/or activate or inhibit the activity of GPR14 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 15, 2003
    Publication date: July 20, 2006
    Applicant: Bayer Healthcare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060110783
    Abstract: The invention provides a human PDE10A which is associated with the disorders of the peripheral and central nervous system (e.g. Alzheimer), cardiovascular diseases, cancer (e.g. thyroid, oesophagus, stomach, liver, ovary, kidney), gastroenterological diseases (e.g. liver cirrhosis), endocrinological diseases and urological diseases (e.g. benign prostate hyperplasia). The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardiovascular diseases, cancer, gastroenterological diseases, endocrinological diseases and urological diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of PDE10A as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: October 25, 2003
    Publication date: May 25, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060057577
    Abstract: The invention provides a human FPRL2 which is associated with the cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, cns disorders, hematological diseases, genito-urinary diseases, cancer and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FPRL2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 10, 2003
    Publication date: March 16, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Greets
  • Publication number: 20060057143
    Abstract: The invention provides a human CCR11 which is associated with the disorders of the peripheral and central nervous system, cardio-vascular diseases, genitourinary diseases, metabolic diseases and hematological diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of disorders of the peripheral and central nervous system, cardio-vascular diseases, genitourinary diseases, metabolic diseases and hematological diseases. he invention also features compounds which bind to and/or activate or inhibit the activity of CCR11 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 12, 2003
    Publication date: March 16, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060057648
    Abstract: The invention provides a human NMU1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, inflammation diseases, cancer diseases, and disorders of the liver. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, inflammation diseases, cancer diseases, and disorders of the liver. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: January 24, 2003
    Publication date: March 16, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Greets
  • Publication number: 20060040266
    Abstract: The invention provides a human NMU2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, cancer, genitourinary diseases and respiratory diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of NMU2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: May 14, 2003
    Publication date: February 23, 2006
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20060014218
    Abstract: The invention provides a human NPFF1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma and genito-urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma and genito-urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NPFF1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: January 19, 2006
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Bernhard Weingartner
  • Publication number: 20050255529
    Abstract: The present invention is directed to novel uses of a polynucleotide sequence of a novel G-Protein Coupled Receptor 5HT6. The invention also provides the human 5-HT6 receptor as being associated with hematological disorders, pain diseases, respiratory diseases, genito-urological disorders, cardio vascular diseases and cancer. The invention also provides assays for the identification of compounds useful for the modulation of hematological disorders, pain diseases, respiratory diseases, genito-uro-logical disorders, cardio vascular diseases and cancer for treating or preventing hematological disorders, pain diseases, respiratory diseases, genito-urological disorders, cardio vascular diseases and cancer associated with expression of the 5-HT6 receptor.
    Type: Application
    Filed: January 20, 2003
    Publication date: November 17, 2005
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20050244896
    Abstract: The invention provides a human NPFF2 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, and genito-urological disorders. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, and genito-urological disorders. The invention also features compounds which bind to and/or activate or inhibit the activity of NPFF2 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 21, 2003
    Publication date: November 3, 2005
    Inventors: Stefan Golz, Ulf Bruggemeier, Bernhard Weingartner
  • Publication number: 20050164298
    Abstract: The invention provides a human GHS which is associated with the cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD and asthma, hematological diseases, cancer, gastro-intestinal diseases and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of GHS as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 14, 2003
    Publication date: July 28, 2005
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20050164305
    Abstract: The invention provides a human FPRL1 which is associated with the hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also provides assays for the identification of compounds useful in the treatment or prevention of hematological diseases, cardiovascular diseases, disorders of the peripheral and central nervous system, respiratory diseases like COPD, asthma, genito-urological disorders and inflammation diseases. The invention also features compounds which bind to and/or activate or inhibit the activity of FPRL1 as well as pharmaceutical compositions comprising such compounds.
    Type: Application
    Filed: March 21, 2003
    Publication date: July 28, 2005
    Applicant: Bayer HealthCare AG
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20050043511
    Abstract: Polynucleotide sequence for novel G-protein coupled receptor LUSTR2 and uses thereof. The present invention is directed to a polynucleotide sequence of a novel G-Protein Coupled Receptor LUSTR2. More particularly, the present invention provides a polynucleotide sequence comprising the nucleic acid sequence SEQ ID NO: 1 or nucleic acid sequences that hybridize to SEQ ID NO: 1 or its complimentary strand having at least 40% sequence identity. Preferably, the hybridizing nucleic acid sequence should hybridize under stringent conditions and in particular have 85% sequence identity, more preferably 90% sequence identity, and most preferably 95% sequence identity. The invention also provides the human LUSTR2 associated with the hemaotological, peripheral and central nervous system, COPD, asthma, genito-urological, metabolic diseases and pancreas and heart disorders as a result of relative quantification of the mRNA distribution in different human tissues by expression profiling.
    Type: Application
    Filed: November 15, 2002
    Publication date: February 24, 2005
    Inventors: Stefan Golz, Ulf Bruggemeier, Andreas Geerts
  • Publication number: 20040122076
    Abstract: The present invention relates to the use of sulphonamides for the production of a medicament for the prophylaxis and/or treatment of diseases which are treatable using a 5-HT6 antagonist, in particular of diseases of the central nervous system.
    Type: Application
    Filed: October 1, 2003
    Publication date: June 24, 2004
    Inventors: Frank-Gerhard Bobb, Ulf Bruggemeier, Stephan-Nicolas Wirtz
  • Patent number: 6495545
    Abstract: The present invention relates to compounds of general formula (I) and their preparation and use for the production of pharmaceuticals, and pharmaceuticals comprising these compounds.
    Type: Grant
    Filed: June 12, 2001
    Date of Patent: December 17, 2002
    Assignee: Bayer Aktiengesellschaft
    Inventors: Klaus Urbahns, Delf Schmidt, Ulf Brüggemeier, Christoph Gerdes, Beatrix Stelte-Ludwig, Jörg Keldenich, Elke Stahl
  • Patent number: 5723031
    Abstract: The method permits the non-destructive analytical detection and/or the quantification of viruses or viral particles (analytes) in a liquid sample matrix containing organic or inorganic minor constituents, in particular protein moieties and/or nucleotides and/or other viruses. To this end the viruses or the viral particles are separated from the protein moieties and/or nucleotides in the sample matrix using capillary electrophoresis and at the same time the electropherogram associated therewith is recorded. The fractions assigned to the analytes can then be identified as virus peaks in the electropherogram by spectroscopic interpretation with the aid of characteristic maxima. For better identification, a reference sample of a known virus or of a known viral particle can be added to the sample matrix.
    Type: Grant
    Filed: October 24, 1995
    Date of Patent: March 3, 1998
    Assignee: Bayer Aktiengesellschaft
    Inventors: Hansjorg Durr, Hans-Robert Hehnen, Lothar Helbig, Roberto Correa, Ulf Bruggemeier